Title: Open-Label Pilot Clinical Trial On the Anti-Hypertensive Effect of a Novel Dietary Nitrate Supplement In Adults Attending a Cardiac Rehabilitation Clinic.

Background: There is growing evidence for the role of inorganic nitrate supplements in the management of hypertension via their conversion to the vasodilator, nitric oxide. In the U.S. and globally, the majority of adults do not consume enough fruit and vegetables to meet daily recommendations. The widespread deficit in antioxidants, phytochemicals, and nutrients from fruit and vegetables is a contributing factor to almost every chronic condition, especially cardiovascular disease. Furthermore, emerging evidence suggests that low endogenous nitric oxide levels may play a role in the pathogenesis of many diseases, including pulmonary, renal, metabolic, endocrine, gastrointestinal/hepatic, and cardiovascular diseases. As concentrated sources of dietary nitrate, fruits like aronia berry, and vegetables such as beets, red spinach, and other leafy greens may play a crucial role in promoting health via mechanisms involving production of nitric oxide, enhancing blood flow, supporting antioxidant activity, promoting a positive microbiome, and regulating inflammation. This open-label, exploratory, pilot clinical trial aimed to evaluate the effect of a proprietary nitric oxide supplement made from natural ingredients, Resync Recovery, in the management of cardiovascular risk factors in a population of mostly hypertensive adults attending a cardiac rehabilitation clinic, HeartFit, in Calgary, Canada.

Methods: Twenty-eight participants were recruited into the study. Cardiovascular function was at baseline and weekly thereafter for 5 total weeks. Participants were instructed to take either one or two 7.66g servings of Resync Recovery depending on their initial central blood pressure reading. If the initial blood pressure was >130/80, two servings were indicated, one in the morning and one in the evening. If one serving was suggested, it was to be taken in the morning.

Results: 79% of participants had baseline blood pressure readings above 130/80. Twenty-one patients completed 4 weeks of treatment; six participants completed 5 weeks of treatment. Four of ten patients had baseline endothelial function tests, only one completed final measurement. High loss to follow up is likely attributable to Covid-19 pandemic and data appears to be missing at random. One participant was excluded from data due to external variables causing unusual changes to blood pressure. Clinically relevant decreases in many indices of cardiovascular function were observed. Statistically significant differences were observed at multiple time points relative to baseline. Acute (1 week of treatment) mean decrease in blood pressure was 7.80/2.31 (SBP p=.061), pulse pressure decreased 13.75% (p<.05). From baseline to time point 5 (4 weeks of treatment) mean decrease in blood pressure was 4.28/1.40. From baseline to final time point (5 weeks of treatment), mean decrease was 8.11/8.43 (DBP p<.05), mean arterial pressure decreased by 9.80 (9.38%; p<.05), and aortic augmentation index decreased by 14.42%. When data was stratified by top 50% and bottom 50% of baseline blood pressure among those receiving two servings of Resync Recovery, baseline to week 1 mean decrease in blood pressure for the upper 50% of participants was 12.5/4.0; baseline to week 6 mean decrease was 23.0/19.3. Baseline to week 1 mean decrease in blood pressure for the lower 50% of participants was .6/.9; baseline to week 6 mean decrease was 2.8/1.8. Data show clinically relevant and statistically dsignificant decreases in pulse pressure and central blood pressure. No major side effects or adverse events were noted.

Conclusion: Resync Recovery may reduce blood pressure in hypertensive individuals when taken appropriately. This data suggests that those with the highest baseline blood pressure benefit the most from the anti-hypertensive effects of Resync recovery. Normo-tensive individuals’ blood pressure may have an adaptive response to the supplement (whereby blood pressure returns to baseline after an acute, 1 week decrease), whereas those with most severe hypertension do not appear to have an adaptive effect (ie. lowered blood pressure was sustained for 5 weeks).

Title: Open-Label Pilot Clinical Trial On the Anti-Hypertensive Effect of a Novel Dietary Nitrate Supplement In Adults Attending a Cardiac Rehabilitation Clinic.
Abstract

Background: There is growing evidence for the role of inorganic nitrate supplementation in the management of hypertension via their conversion to the vasodilator, nitric oxide. This open-label, exploratory, pilot clinical trial aimed to evaluate the effect of a proprietary nitric oxide supplement, Resync Recovery, in the management of blood pressure (BP) and endothelial function in a population of mostly hypertensive adults attending a cardiac rehabilitation clinic, Heartfit, in Calgary, Canada.

Methods: Twenty-eight participants were recruited into the study. Cardiovascular function was assessed by endothelial function test (EFT), mean arterial pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), and aortic augmentation index (AI). Ten patients were recruited into EFT measurements. Participants were instructed to take either one (7.66g) or two servings of Resync Recovery depending on their initial central blood pressure reading. If participant initial blood pressure was >130/80, two servings were indicated, one in the morning and one in the evening. For those with BP <130/80, one serving in the morning was suggested. Readings were taken at the same time of day, weekly for five weeks following the initial reading.

Results: Mean age of participants was 64.6 years at baseline and majority Male / Female. 79% of participants had baseline SBP greater than 130 or DBP greater than 80. Twenty-one patients completed the study to the penultimate time point (4 weeks of treatment), six participants completed all 5 weeks treatment. Four of ten patients had baseline EFT measurements, only one completed final EFT measurement. High loss to follow up is likely attributable to Covid-19 pandemic and data is assumed to be missing at random. One participant was excluded from data due to external variables causing unusual changes to blood pressure.

Clinically relevant decreases in many indices of cardiovascular function were observed. Using two-sample T-tests assuming unequal variances, statistically significant differences were observed at multiple time points relative to baseline. Acute (1 week of treatment) mean effects were: MAP decreased 4.92 (4.71%), PP decreased 6.80 (13.75%; p<.05), SBP decreased 7.80 (5.81%; p=.061), DBP decreased 2.31 (2.69%), AI decreased 3.72 (12.03%). From baseline to time point 5 (4 weeks of treatment) mean effects were: MAP decreased by 2.82 (2.70%), PP decreased by 4.21 (8.50%), SBP decreased by 4.28 (3.19%), DBP decreased by 1.40 (1.63%), and AI decreased by 1.14 (3.68%). From baseline to final time point (5 weeks of treatment), mean effects were: MAP decreased by 9.80 (9.38%; p<.05), PP decreased by 1 (2.02%), SBP decreased by 8.11 (6.04%), DBP decreased by 8.43 (9.81%; p<.05), AI decreased by 4.46 (14.42%). Data for participants remaining in trial to final measurement was normally distributed and assumed to be independent of unmeasured covariates (ie. “missing at random”), however caution is warranted due to small sample size (n≤6). In exploratory analysis, data was stratified by top 50% and bottom 50% of baseline blood pressure among those receiving two servings of Resync Recovery. Acute (baseline to week 1) mean decrease in blood pressure for the upper 50% of participants was 12.5/4.0; baseline to week 6 mean decrease was 23.0/19.3. Acute mean decrease in blood pressure for the lower 50% of participants was .6/.9; baseline to week 6 mean decrease was 2.8/1.8. Data suggests that normo-tensive individuals’ blood pressure may have an adaptive response to the supplement (whereby blood pressure returns to baseline after an acute, 1 week decrease), whereas those with most severe hypertension do not appear to have an adaptive effect (ie. lowered blood pressure was sustained for 5 weeks). No major side effects or adverse events were noted.

Conclusion: Resync Recovery may reduce blood pressure in hypertensive individuals when taken appropriately. Those with the highest baseline blood pressure benefit the most from the anti-hypertensive effects of two doses of Resync Recovery.

Resync is the first and only patent pending athletic recovery supplement with key natural extracts of Red Spinach, Red Beets, and Aronia Berry used, as well as being supported by additional clinically proven ingredients to improve daily vitality, cardiovascular health and athletic recovery.

We always suggest speaking with your doctor for the best dosing and timing of taking Resync. Those with low blood pressure, it's recommended to be taken with food.

We recommend taking 1-2 servings a day.

A single serving of Resync can be taken with 8-16oz of water or any other beverage of your choice. It mixes well with protein shakes, smoothies, and can be a great addition to snacks as well. Be sure to stir it well.

Since Resync is a supplement, we always recommend that you consult with your physician prior to consumption.

Resync Recovery Blend in both 20 serving tub and sachet packaging are vegan.

Resync Collagen Blend contains Types I & III hydrolyzed collagen peptides derived from a bovine source, therefore are not vegan. 

Like other supplements, it is recommended to speak to your doctor prior to consumption.

The ingredients in Resync are safe for consumption. We recommend that children take one serving a day, whereas adults can take up to two. If you are still not sure if Resync is right for your child, consult with your pediatrician.

Yes. We invite everyone to close the gap between tired and refreshed to support recovery from all day activities and performance on a daily basis.

Resync helps people live healthier lives.

Resync does not contain any allergens (soy, dairy, eggs, shellfish, fish, tree nuts, wheat, peanuts of 8 allergens on the FDA list).

Absolutely! In fact, for the best effect, we recommend taking Resync Collagen in the morning and Resync Recovery Blend in the evening